EPO and anemia: Recombinant human erythropoietin (rhEPO) or its analogs (erythropoiesis-stimulating agents [ESAs]) and iron supplementation (intravenous and/or oral) represent the current standard of treatments for CKD patients with anemia (Drüeke and Parfrey, 2012).